Citations

Showing 10 of 108119 citations.

Association of peripheral artery disease with in‐hospital outcomes after endovascular transcatheter aortic valve replacement
Mohananey, Divyanshu , Villablanca, Pedro , Ando, Tomo , Wang, Dee Dee , Wiley, José , Eng, Marvin H. , Shah, Binita , Saucedo, Jorge , Bhatt, Deepak L. , Ando, Tomo , Wang, Dee Dee , Eng, Marvin , Ramakrishna, Harish , Bhatt, Deepak L , Shah, Binita , Gupta, Tanush , Ranka, Sagar , Bhatia, Nirmanmoh , Adegbala, Oluwole Muyiwa , Kalra, Ankur , O’Neill, William W.

Mayo Clinic

Catheterization and Cardiovascular Interventions | April 26, 2019 | Volume: 94 | Issue: 2 | Pages: 249-255

10.1002/ccd.28310 | PMID 31025488 Get It

AbstractObjectivesThe aim of this study was to determine the prevalence of peripheral artery disease (PAD) and its association with in‐hospital outcomes after endovascular transcatheter aortic valve replacement (EV‐TAVR).BackgroundTAVR is an established treatment for patients at prohibitive, high, or intermediate surgical risk. PAD is a significant comorbidity in the determination of surgical risk. However, data on association of PAD with outcomes after EV‐TAVR are limited.MethodsPatients in the National Inpatient Sample who underwent EV‐TAVR between January 1, 2012 and September 30, 2015 were evaluated. The primary outcome was in‐hospital mortality.ResultsA total of 51,685 patients underwent EV‐TAVR during the study period. Of these, 12,740 (24.6%) had a coexisting diagnosis of PAD. The adjusted odds for in‐hospital mortality [OR 1.08 (95% CI 0.83–1.41)], permanent pacemaker implantation [OR 0.98 (0.85–1.14)], conversion to open aortic valve replacement [OR 1.05 (0.49–2.26)], or acute myocardial infarction [OR 1.31(0.99–1.71)] were not different in patients with versus without PAD. However, patients with PAD had greater adjusted odds of vascular complications [OR 1.80 (1.50–2.16)], major bleeding [OR 1.20 (1.09–1.34)], acute kidney injury (AKI) [OR 1.19 (1.05–1.36)], cardiac complications [aOR 1.21 (1.01–1.44)], and stroke [OR 1.39(1.10–1.75)] compared with patients without PAD. Length of stay (LOS) was significantly longer for patients with PAD [7.23 (0.14) days vs. 7.11 (0.1) days, p < 0.001].ConclusionOf patients undergoing EV‐TAVR, ~25% have coexisting PAD. PAD was not associated with increased risk of in‐hospital mortality but was associated with higher risk of vascular complications, major bleeding, AKI, stroke, cardiac complications, and longer LOS.
Telomere Length and Risk of Major Adverse Cardiac Events and Cancer in Obstructive Sleep Apnea Patients
Polonis, Katarzyna , Sompalli, Sreeja , Becari, Christiane , Xie, Jiang , Covassin, Naima , Schulte, Phillip J. , Druliner, Brooke R., Johnson, Ruth, Narkiewicz, Krzysztof , Boardman, Lisa A, Singh, Prachi , Johnson, Ruth A, Singh, Prachi , Druliner, Brooke R. , Boardman, Lisa A, Somers, Virend K.

Mayo Clinic

Cells | April 26, 2019 | Volume: 8 | Issue: 5 | Pages: 381

10.3390/cells8050381 | PMID 31027347 Get It

Telomere length (TL) is associated with cardiovascular disease (CVD) and cancer. Obstructive sleep apnea (OSA) is also linked to higher risk of CVD and cancer, and to TL. We investigated the association between TL and risk of major adverse cardiac events (MACE) and cancer in OSA patients. We studied 210 individuals undergoing sleep-related studies between 2000 and 2007. Baseline characteristics and follow-up data (available in 164 subjects) were obtained from clinic records. Incidence rates were calculated for the entire group and by OSA status. Hazard ratios were calculated to estimate effects of OSA and TL on risk of MACE and cancer. In total, 32 individuals (20%) developed MACE and/or cancer during 12.7-year follow-up. The OSA group had a higher likelihood of cancer (16.0 vs. 4.9 events per 1000 person-years, P = 0.044) but no clear evidence of an elevated incidence of MACE (10.8 vs. 4.8 events per 1000 person-years, P = 0.293) compared to the non-OSA group. There was no association between TL and MACE- (HR = 1.01, 95% CI 0.78–1.28), or cancer-risk (HR = 1.18, 95% CI 0.96–1.43). Our study warrants further investigation of any modulating effect of OSA on TL and the risk of MACE and cancer.
Glioma “Liquid Biopsy”: A New Frontier in Neurosurgery
Abi-Aad, Karl R., Acis, Onur, Welz, Matthew E., Bendok, Bernard R. , Acıs, Onur

Mayo Clinic

Neurosurgery | April 25, 2019 | Volume: 85 | Issue: 2 | Pages: E203-E204

10.1093/neuros/nyz165 | PMID 31304542 Get It

Intrathecal gadolinium: a fatal flaw
Maus, Timothy P. , Maus, Timothy

Mayo Clinic

Regional Anesthesia & Pain Medicine | April 25, 2019 | Volume: 44 | Issue: 7 | Pages: 687-688

10.1136/rapm-2019-100603 | PMID 31023930 Get It

Delayed implant infection with Cutibacterium acnes (Propionibacterium acnes) 30 years after silicone sheet orbital floor implant
Vichitvejpaisal, Pornpattana, Lally, Sara E. , Dalvin, Lauren A. , Shields, Carol L.

Mayo Clinic

Orbit | April 25, 2019 | Volume: 39 | Issue: 2 | Pages: 139-142

10.1080/01676830.2019.1605613 | PMID 31021283 Get It

Update on spinal epidural abscess
Babić, Maja , Simpfendorfer, Claus, Berbari, Elie F.

Mayo Clinic

Current Opinion in Infectious Diseases | April 25, 2019 | Volume: 32 | Issue: 3 | Pages: 265-271

10.1097/qco.0000000000000544 | PMID 31021957 Get It

Purpose of review Spinal epidural abscess (SEA) is still a rare but potentially very morbid infection of the spine. In recent years, the incidence has risen sharply but the condition remains a medical conundrum wrought with unacceptably long diagnostic delays. The outcome depends on timely diagnosis and missed opportunities can be associated with catastrophic consequences. Management and outcomes have improved over the past decade. This review focuses on risk factors and markers that can aid in establishing the diagnosis, the radiological characteristics of SEA on MRI and their clinical implications, as well as the importance of establishing clear indications for surgical decompression. Recent findings This once exclusively surgically managed entity is increasingly treated conservatively with antimicrobial therapy. Patients diagnosed in a timely fashion, prior to cord involvement and the onset of neurologic deficits can safely be managed without decompressive surgery with targeted antimicrobial therapy. Patients with acute cord compression and gross neurologic deficits promptly undergo decompression. The greatest therapeutic dilemma remains the group with mild neurological deficits. As failure rates of delayed surgery approach 40%, recent research is focused on predictive models for failure of conservative SEA management. In addition, protocols are being implemented with some success, to shorten the diagnostic delay of SEA on initial presentation. Summary SEA is a potentially devastating condition that is frequently missed. Protocols are put in place to facilitate early evaluation of back pain in patients with red flags with appropriate cross-sectional imaging, namely contrast-enhanced MRI. Efforts for establishing clear-cut indications for surgical decompression of SEA are underway.
Impact of hepatitis C sustained viral response on cardiovascular diseases: a meta-analysis
Lapumnuaypol, Kamolyut , Thongprayoon, Charat , Wijarnpreecha, Karn , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Thongprayoon, Charat , Wijarnpreecha, Karn

Mayo Clinic

Hospital Practice | April 25, 2019 | Volume: 47 | Issue: 3 | Pages: 105-110

10.1080/21548331.2019.1612066 | PMID 31018721 Get It

PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network
Chamberlain, Alanna M. , Shaw, Kathryn M., Bian, Jiang , Song, Wen‐Liang , Guhl, Emily , Shah, Rashmee U. , Puro, Jon , Pawloski, Pamala A. , Margolis, Karen L. , Chamberlain, Alanna M , Bian, Jiang , Shah, Rashmee U , Gong, Yan , Linton, MacRae F. , Fonseca, Vivian , Price‐Haywood, Eboni G. , King, Jordan B. , Shenkman, Elizabeth , Hernandez, Adrian F. , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Journal of the American Heart Association | April 25, 2019 | Volume: 8 | Issue: 9 | Pages: No page available

10.1161/jaha.118.011246 | PMID 31020929 Get It

Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low‐density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high‐risk patients. We used real‐world electronic health record data to characterize use of PCSK9 inhibitors, in addition to standard therapies, according to cardiovascular risk status. Methods and Results Data were obtained from 18 health systems with data marts within the National Patient‐Centered Clinical Research Network (PCORnet) using a common data model. Participating sites identified >17.5 million adults, of whom 3.6 million met study criteria. Patients were categorized into 3 groups: (1) dyslipidemia, (2) untreated LDL ≥130 mg/dL, and (3) coronary artery disease or coronary heart disease. Demographics, comorbidities, estimated 10‐year atherosclerotic cardiovascular disease risk, and lipid‐lowering pharmacotherapies were summarized for each group. Participants’ average age was 62 years, 50% were female, and 11% were black. LDL cholesterol ranged from 85 to 151 mg/dL. Among patients in groups 1 and 3, 54% received standard lipid‐lowering therapies and a PCSK9 inhibitor was prescribed in <1%. PCSK9 inhibitor prescribing was greatest for patients with coronary artery disease or coronary heart disease and, although prescribing increased during the study period, overall PCSK9 inhibitor prescribing was low. Conclusions We successfully used electronic health record data from 18 PCORnet data marts to identify >3.6 million patients meeting criteria for 3 patient groups. Approximately half of patients had been prescribed lipid‐lowering medication, but <1% were prescribed PCSK9 inhibitors. PCSK9 inhibitor prescribing increased over time for patients with coronary artery disease or coronary heart disease but not for those with dyslipidemia.